CT
CTMX.US CytomX Therapeutics Inc
- Market cap
- USD 445M
- P/E
- -
- P/B
- 1.56x
- ROE
- -27.6%
- Dividend yield
- 0.68%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CTMX.US undervalued?
Graham numberThe Graham number of CytomX Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CytomX Therapeutics Inc fundamental analysis
No fundamental analysis for CytomX Therapeutics Inc yet.
CytomX Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index fo…
Full company profileCytomX Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CytomX Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.0M | 71.6M | 59.5M | 57.5M | 68.4M | 69.6M | 53.2M | 101M | 138M | 76.2M | 17.8M |
| Gross Profit | 15.0M | 71.6M | 59.5M | 57.5M | 68.4M | 69.6M | 53.2M | 101M | 138M | 76.2M | 17.5M |
| Operating Income | -59.6M | -46.3M | -77.9M | -111M | -80.5M | -83.8M | -101M | -6.48M | 25.0M | -22.4M | -89.3M |
| EBITDA | -57.9M | -42.0M | -76.0M | -108M | -78.0M | -81.1M | -98.9M | 5.50M | 33.9M | -15.8M | -82.1M |
| Net Income | -58.9M | -43.1M | -84.6M | -102M | -64.8M | -80.6M | -97.3M | -569K | 31.9M | -17.4M | -78.5M |
| EPS | -1.63 | -1.16 | -2.03 | -2.26 | -1.40 | -1.26 | -1.48 | -0.01 | 0.38 | -0.13 | -0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 199M | 398M | 457M | 341M | 359M | 339M | 261M | 202M | 121M | 152M | 365M |
| Total Liabilities | 121M | 328M | 326M | 290M | 366M | 250M | 347M | 249M | 121M | 52.6M | 79.8M |
| Shareholders' Equity | 78.5M | 69.9M | 131M | 51.1M | -7.77M | 89.4M | -85.8M | -47.4M | -456K | 99.0M | 285M |
| Cash & Short-term Investments | 182M | 374M | 436M | 296M | 316M | 305M | 194M | 175M | 101M | 137M | 348M |
| Total Debt | - | - | - | 27.7M | 24.9M | 18.1M | 18.1M | 14.0M | 9.39M | 4.24M | 4.39M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.03M | 170M | -75.5M | -140M | 5.26M | -119M | -111M | -56.0M | -86.2M | -75.6M | -36.0M |
| Capital Expenditure | 2.18M | 1.56M | 3.79M | 3.50M | 2.31M | 1.61M | 1.74M | 840K | 310K | 220K | 785K |
| Free Cash Flow | -4.21M | 169M | -79.3M | -144M | 2.95M | -121M | -113M | -56.9M | -86.5M | -75.8M | -36.7M |
| Ratios | |||||||||||
| ROE | -75.1% | -61.7% | -64.6% | -200.0% | - | -90.2% | - | - | - | -17.5% | -27.6% |
| ROA | -29.6% | -10.8% | -18.5% | -30.0% | -18.1% | -23.8% | -37.3% | -0.3% | 26.4% | -11.5% | -21.5% |
| Net Profit Margin | -391.5% | -60.2% | -142.2% | -177.8% | -94.7% | -115.9% | -183.0% | -0.6% | 23.1% | -22.8% | -440.8% |
| Debt to Equity | - | - | - | 0.54x | - | 0.20x | - | - | - | 0.04x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CytomX Therapeutics Inc dividends
- Dividend yield
- 0.68%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 3.00M | 0.02 | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns CytomX Therapeutics Inc
- Insiders 2.15%
- Institutions 97.85%
- Public & others 0.00%
- Shares outstanding 218M
- Free float 180M
Top funds holding CTMX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 6.23M | 2.86% | 0.00% | Sep 2026 |
| Fidelity Select Health Care | 6.00M | 2.75% | +20.00% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 5.45M | 2.50% | +2.69% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 4.75M | 2.18% | +26.86% | Sep 2026 |
| iShares Russell 2000 ETF | 4.75M | 2.18% | 0.00% | Oct 2026 |
| Fidelity Small Cap Growth | 3.97M | 1.82% | 0.00% | Aug 2026 |
| Fidelity Advisor Health Care I | 3.00M | 1.38% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 2.78M | 1.28% | +0.28% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 2.49M | 1.14% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 1.99M | 0.91% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 1.95M | 0.89% | 0.00% | Aug 2026 |
| iShares Biotechnology ETF | 1.48M | 0.68% | -0.19% | Oct 2026 |
| Fidelity VIP Health Care Initial | 1.18M | 0.54% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 1.10M | 0.50% | +7.22% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 975K | 0.45% | -0.38% | Oct 2026 |
| Fidelity Extended Market Index | 959K | 0.44% | +7.17% | Sep 2026 |
| Fidelity Series Small Cap Core | 955K | 0.44% | +22.58% | Aug 2026 |
| Fidelity Stock Selec | 927K | 0.43% | +0.18% | Sep 2026 |
| iShares Russell 2000 Value ETF | 810K | 0.37% | 0.00% | Oct 2026 |
| Strategic Advisers U.S. Total Stock | 649K | 0.30% | +131.75% | Sep 2026 |
Top institutions holding CTMX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 32.7M | 15.01% | +2.38% | Jun 2026 |
| Kynam Capital Management, LP | 21.7M | 9.96% | +44.56% | Jun 2026 |
| BlackRock Inc | 17.6M | 8.05% | +235.86% | Jun 2026 |
| Bank of America Corp | 15.1M | 6.92% | +47.83% | Jun 2026 |
| State Street Corp | 11.7M | 5.39% | +107.42% | Jun 2026 |
| Perceptive Advisors LLC | 10.4M | 4.79% | +3.37% | Jun 2026 |
| Vanguard Capital Management, LLC | 8.53M | 3.91% | -2.38% | Jun 2026 |
| Point72 Asset Management, L.P. | 7.81M | 3.58% | -0.82% | Jun 2026 |
| Wellington Management Company LLP | 5.17M | 2.37% | +44.26% | Jun 2026 |
| VR Adviser, LLC | 4.98M | 2.29% | -50.09% | Jun 2026 |
| Baker Bros Advisors LP | 4.98M | 2.28% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 4.68M | 2.15% | +126.40% | Jun 2026 |
| Elmind Capital LP | 4.55M | 2.09% | 0.00% | Jun 2026 |
| Nextech Invest, Ltd. | 4.45M | 2.04% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 4.13M | 1.90% | +52.49% | Jun 2026 |
| Eversept Partners, LP | 3.56M | 1.63% | +11.60% | Jun 2026 |
| UBS Group AG | 3.47M | 1.59% | +11.16% | Jun 2026 |
| Siren, L.L.C. | 3.46M | 1.59% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 3.37M | 1.54% | -1.32% | Jun 2026 |
| Citadel Advisors Llc | 3.11M | 1.43% | -42.46% | Jun 2026 |
CytomX Therapeutics Inc company profile
- Company name
- CytomX Therapeutics Inc
- Ticker
- CTMX.US
- Exchange
- USA Stocks
- Listed since
- Oct 8, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- 151 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
- Phone
- 650 515 3185
- Website
- cytomx.com
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
CytomX Therapeutics Inc management
10- Dr. Sean A. McCarthy DPHILChairman & CEO · born 1967
- Mr. Christopher W. OgdenSVP, CFO & Secretary · born 1984
- Ms. Rachael LesterChief Business Officer & Senior VP · born 1978
- Dr. Marcia P. Belvin Ph.D.Senior VP & Chief Scientific Officer · born 1967
- Ms. Alejandra Veronica Carvajal J.D.Chief Legal Officer · born 1974
- Ms. Danielle Olander-MoghadassianSenior VP & Chief Human Resources Officer
- Ms. Leslie Robbins J.D.Senior Vice President of Intellectual Property
- Dr. Yu-Waye Chu M.D.Senior VP & Chief Medical Officer · born 1968
- Ms. Dawn BensonSenior Vice President of Quality & Product Manufacturing
- Dr. Stephanie Robertson Ph.D.Senior Vice President of Alliances & Program Leadership